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Imatinib inhibits the kinase activity of Bcr-Abl and is
currently the most effective drug for treatment of chronic
myeloid leukemia (CML). Imatinib also blocks c-Abl, a
physiological tyrosine kinase activated by a variety of
stress signals including damaged DNA. We investigated
the effect of pharmacological inhibition of c-Abl on
the processing of irradiation-induced DNA damage in
Bcr-Abl-negative cells. Cell lines and peripheral blood
mononuclear cells (PBMCs) from healthy volunteers were
treated with imatinib or dasatinib before c-irradiation.
Inhibition of c-Abl caused an enhanced irradiation-
induced mutation frequency and slowdown of DNA repair,
whereas imatinib was ineffective in cells expressing a
T315I variant of c-Abl. Mutation frequency and repair
kinetics were also studied in c-Abl/ murine embryonic
ﬁbroblasts (MEFs) retransfected with wild-type c-Abl
(wt-Abl) or a kinase-defect variant of Abl (KD-Abl).
Enhanced mutation frequency as well as delayed DNA
repair was observed in cells expressing KD-Abl. These
data indicate that pharmacological inhibition of c-Abl
compromises DNA-damage response.
Oncogene (2008) 27, 4380–4384; doi:10.1038/onc.2008.68;
published online 24 March 2008
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Introduction
The development of imatinib mesylate (STI571, Glee-
vec) for the treatment of chronic myelogenous leukemia
(CML) is one of the most important advances in
malignant disease management during recent years
(Buchdunger et al., 1996; Druker et al., 1996). Imatinib
directly binds to the kinase domain of Bcr-Abl blocking
its activity. In addition, it targets a limited number of
other tyrosine kinases such as c-Abl, c-KIT and platelet-
derived growth factor receptor (Carroll et al., 1997;
Heinrich et al., 2000). Most patients with newly
diagnosed CML achieve durable responses upon
imatinib therapy (Druker et al., 2006). However, even
in patients with complete molecular remission, the
Bcr-Abl-positive clone quickly reappears after discontinua-
tion of imatinib (Michor et al., 2005). Therefore,
prolonged, maybe lifelong therapy is required to control
CML with imatinib. As a consequence, it is of great
importance to understand the biological effects of
imatinib on normal cells. The observation of an
unexpected cardiac toxicity related to c-Abl inhibition
(Kerkela¨ et al., 2006) demonstrates that pharmacologi-
cal targeting of physiological c-Abl is of clinical
relevance.
c-Abl is a tightly regulated cellular tyrosine kinase
involved in several stress signaling pathways. It interacts
with many proteins involved in processing and repair of
DNA damage such as p53 (Wei et al., 2005), p73 (Yuan
et al., 1999), Mdm2 (Goldberg et al., 2002), Rad51
(Yuan et al., 1998), DNA-PK (Kharbanda et al., 1997),
WRN (Cheng et al., 2003), CSB (Imam et al., 2007) and
BRCA1 (Foray et al., 2002). In addition, several studies
have shown that the activity of c-Abl is upregulated
following genotoxic agents or g-irradiation (Shaul and
Ben-Yehoyada, 2005). Therefore, it seems likely that
c-Abl plays an important role for the maintenance
of genetic stability. This prompted us to investigate
whether long-term inhibition of the c-Abl activity affects
genetic stability in Bcr-Abl-negative cells. We analyzed
the frequency of hypoxanthine-guanine phosphoribosyl-
transferase (HPRT) loss-of-function mutations in cell
lines exposed to imatinib and in murine embryonic
ﬁbroblasts (MEFs) expressing either a kinase defect
variant of c-Abl (KD-Abl) or wild type c-Abl (wt-Abl).
As shown in Figure 1a, signiﬁcantly more HPRT
mutant colonies were observed in a g-irradiated Bcr-
Abl-negative cell line in the presence of imatinib. This
contrasts the effect of imatinib observed in Bcr-Abl-
positive cells. We and others found that expression of
the active Bcr-Abl kinase in CML cells results in genetic
instability (Canitrot et al., 1999; Salloukh and Laneu-
ville, 2000; van der Kuip et al., 2004). This can be
partially reversed by imatinib in Bcr-Abl-positive cells
Received 23 October 2007; revised 14 January 2008; accepted 20
February 2008; published online 24 March 2008
Correspondence: Dr H van der Kuip, Dr Margarete Fischer-Bosch
Institute of Clinical Pharmacology, Auerbachstr. 112, 70376 Stuttgart,
Germany.
E-mail: heiko.van-der-kuip@ikp-stuttgart.de
Oncogene (2008) 27, 4380–4384
& 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $30.00
www.nature.com/onc
resulting in mutation frequencies comparable to those
seen in imatinib-treated Bcr-Abl-negative cells
(Figure 1b). Thus, inhibition of c-Abl causes an increase
of the mutation frequency, whereas blocking of Bcr-Abl
activity reduces this frequency. We then asked whether
c-Abl inhibition might contribute to genetic instability
also in Bcr-Abl-positive cells. Therefore, we analyzed
mutation frequency in cells transfected with an imatinib-
resistant bcr-abl mutant (Bcr-AblT315I). As expected, in
cells expressing imatinib-resistant Bcr-Abl and imatinib-
sensitive c-Abl, the HPRT mutation frequency is
signiﬁcantly enhanced in the presence of imatinib
(Figure 1b). To verify that inhibition of c-Abl is the
responsible mechanism for the enhanced mutation
frequency, we examined MEFs derived from c-Abl/
mice retransfected with either KD-Abl or wt-Abl. As
shown in Figure 1c, HPRT mutation frequency was
consistently elevated in cells lacking c-Abl kinase
activity. We conclude that inhibition of c-Abl compro-
mises mechanisms responsible for the maintenance of
genomic integrity.
It has been shown that activation of c-Abl by many
sources of DNA damage is associated with inhibition of
cell growth and induction of apoptosis (Kharbanda
et al., 1998; Wang, 2000). Therefore, we examined
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Figure 1 Inﬂuence of imatinib on mutation frequencies in Bcr-Abl-
positive and Bcr-Abl-negative cells. 32D and BaF3 cell lines are
described elsewhere (Moehring et al., 2005). The immortalized Abl/
MEFs were a kind gift fromDrWang (UCSD, San Diego, CA, USA).
The cells were reconstituted with KD-Abl, or wt-Abl by retroviral
infection. Cells were cultivated in RPMI1640/10% FCS complemented
with 1ngml1 mIL-3 for BaF3 and 32D cells. Cells were treated with
or without imatinib (Toronto Research Chemicals Inc., North York,
Ontario, Canada) and irradiated three times (2Gy) over a time period
of 10 days before 6-TG selection. Imatinib was used at concentrations
of 1 or 3mM. Preliminary experiments showed that these concentra-
tions are sufﬁcient to completely inhibit irradiation-induced c-Abl
activity in all cell lines used (not shown). The concentrations are in the
range of those found in plasma from patients treated with 400 or
600mg imatinib (Picard et al., 2007). The HPRT mutation frequency
was evaluated as described (van der Kuip et al., 2004). For each single
experiment, the mean value of six-well plates for CE and 12-well plates
for selection of 6-TG resistant colonies were used for calculation.
(a) g-irradiation induced mutation frequency in BaF3 cells treated with
or without 1mM imatinib. Values reﬂect the mean±s.e.m. of six
independent examinations. (b) HPRT mutation frequency in Bcr-
Abl-positive 32D cells (BAþ ), 32D cells expressing the imatinib-
resistant bcr-abl mutant T315I (Bcr-AblT315I), and Bcr-Abl-negative
32D cells (BA) in the presence or absence of 3mM imatinib.
Values reﬂect the mean±s.e.m. of six independent examinations.
(c) Frequency of 6-TG resistant clones in MEFs expressing a
KD- or wt-Abl. Values reﬂect mean±s.e.m. of six independent
examinations. (*Po0.05, two-sided paired Student’s t-test). CE,
cloning efﬁciency; FCS, fetal calf serum; HPRT, hypoxanthine-guanine
phosphoribosyltransferase; KD-Abl, kinase defect variant of c-Abl;
MEFs, murine embryonic ﬁbroblasts; RPMI, Roswell Park Memorial
Institute medium; TG, thioguanine; wt-Abl, wild-type c-Abl.
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Figure 2 Imatinib treatment of Bcr-Abl-negative cells has no
effect on proliferation or induction of apoptosis. (a) 32D cells were
treated with or without 3mM imatinib and irradiated three times
(2Gy) over a time period of 10 days. Medium and/or imatinib were
changed every other day. Cells were counted every 48 h and the
number of cell divisions was calculated (left panel). Cells were
resuspended in semisolid RPMI containing 0.3% agar and plated
at a density of 200 cells/well (six-well plates). Cells were then
incubated for 7 days. Colonies larger than 50 cells were counted to
determine CE (right panel). Values reﬂect mean±s.e.m. of ﬁve
independent examinations. (b) 32D cells were pretreated with or
without 3mM imatinib for 48 h before irradiation with indicated
dosages. Cell death was assessed by FITC-conjugated Annexin V
staining (Pharmingen, San Diego, CA, USA) at indicated time
points after irradiation. The staining was performed according to
manufacturers’ instructions and analyzed by ﬂow cytometry.
Values reﬂect mean±s.e.m. of three independent examinations.
CE, cloning efﬁciency; FITC, ﬂuorescein isothiocyanate; RPMI,
Roswell Park Memorial Institute medium.
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Figure 3 c-Abl activity inﬂuences DNA strand break repair kinetics. The time course of repair kinetics was evaluated by comet assay.
Following preincubation with/without imatinib or dasatinib (Toronto Research Chemicals Inc., Ontario, Canada) for 48 h, cells were
irradiated with 30Gy. Cells were harvested at indicated time points. The comet assay was performed according to Singh et al. (1988). In
brief, a suspension of 160 000 cells in 0.5% low melting point agarose was placed onto precoated slides. Lysis was performed for 10min
in 2.5M NaCl, 0.1M EDTA, 10mM Tris, 1% Triton X-100, pH 10. The slides were transferred into electrophoresis buffer (300mM
NaCl, 1mM EDTA). Electrophoresis was conducted at 4 1C (15min, 25V, 300mA). The slides were neutralized with 0.4M Tris, pH 7.5
and stained with DAPI-Vectashield (Vector, UK). At least 50 cells of each slide were randomly selected and evaluated using a DMRM
microscope (Leica, Germany) and a computer-based image analysis system (TriTec Corp., Virginia, USA). Each experiment was
conducted in independent triplicates. The mean value of the percentage of DNA in tail was taken as an indicator of DNA strand
breaks. (a) 32D cells (left panels) and PBMCs from healthy volunteers (right panels) were treated with or without 3 mM imatinib (upper
panels) or 10 nM dasatinib (lower panels) for 48 h before g-irradiation (30Gy). At indicated time points after irradiation, cells were
harvested and the percentage of DNA in tail was evaluated as equivalent for DNA strand breaks. PBMCs were isolated by Ficoll–
Hypaque gradient centrifugation (Seromed, Germany) and grown in RPMI1640/10% FCS supplemented with 2mgml1 PHA (Sigma,
Germany). (b) Immortalized MEFs derived from c-Abl-null mice retransfected with either a kinase-defect variant of c-Abl or a wild
type c-Abl were harvested after indicated time points after g-irradiation (30Gy) and analyzed using comet assay. (c) Imatinib-
insensitive 32D c-AblT315I cells were treated with or without 3mM imatinib for 48 h and harvested at indicated time points after
g-irradiation (30Gy) for quantiﬁcation of DNA damage by comet assay. 32D cells were stably transfected with an HA-tagged type IV
c-ablT315I cDNA cloned into pcDNA3.1zeo () (Invitrogen, Karlsruhe, Germany). The T315I mutation was introduced by
site-directed mutagenesis. (**Po0.001, ***Po0.0001, unpaired Student’s t-test). EDTA, ethylenediaminetetraacetic acid; FCS, fetal
calf serum; HA, hemagglutinin; MEFS, murine embryonic ﬁbroblasts; PBMCs, peripheral blood mononuclear cells; PHA,
phytohemagglutinin.
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whether the effect of c-Abl inhibition on genetic stability
is due to differences in cell proliferation and induction of
apoptosis. Treatment with imatinib neither affected the
total number of cell doublings over a 10-day cultivation
period nor long-term clonogenic survival in 32D and
BaF3 cells (Figure 2a). In addition, induction of cell
death following irradiation was not signiﬁcantly altered
by imatinib in 32D or BaF3 cells (Figure 2b).
Proteins involved in DNA repair are among the well-
characterized targets of the c-Abl kinase. To address the
question whether imatinib may interfere with the
kinetics of g-irradiation-induced DNA strand break
repair, we performed comet assays in murine cell lines
and primary human peripheral blood mononuclear cells
(PBMCs) from healthy volunteers. The upper panel of
Figure 3a shows the kinetics of DNA strand break
repair in Bcr-Abl-negative cell lines (left panel) and in
PBMCs (right panel) in the presence or absence of
imatinib. Imatinib had no effect on the peak amount of
irradiation-induced DNA strand breaks (Figure 3a, time
0) or on constitutive breaks in non-irradiated controls
(not shown). However, pretreatment with imatinib
signiﬁcantly impaired the efﬁciency of DNA repair
(Figure 3a, upper panel). This phenomenon was also
observed in BaF3 cells and with different doses of
irradiation (3 and 5Gy; not shown). We next investi-
gated if other c-Abl inhibitors such as dasatinib also
affect DNA repair. As shown in Figure 3a (lower panel),
a comparable delay of DNA repair was observed with
dasatinib in all cells tested including PBMCs from
healthy volunteers (not shown for BaF3 cells). To
further verify that this phenomenon is caused by
inhibition of c-Abl, we examined the repair kinetics in
MEFs expressing either KD-Abl or wt-Abl. Cells
expressing the kinase-defect form again showed a
signiﬁcant delay in DNA repair compared to cells
transfected with wt-Abl (Figure 3b). To exclude imatinib
effects unrelated to c-Abl inhibition, we generated a cell
line transfected with an imatinib-resistant c-Abl con-
struct (c-AblT315I). Expression of this c-Abl variant
was sufﬁcient to completely abolish the effect of
imatinib on the kinetics of DNA repair (Figure 3c).
In conclusion, our experiments demonstrate
that inhibition of c-Abl both affects the velocity of
DNA repair and the maintenance of genetic
stability. These phenomenons are caused by deﬁcient
c-Abl kinase activity irrespective whether genetic or
pharmacological methods were applied. c-Abl
activity plays a role in DNA repair processes, prolifera-
tion and induction of apoptosis (Kharbanda et al.,
1998). The ultimate Abl-dependent response to
DNA damage may depend on the cell type as well as
on the type of DNA damage induced. Our results
suggest that in hematopoietic cells, c-Abl inhibition
alters DNA repair processes rather than survival
after irradiation. In accordance with this, Uemura and
Grifﬁn (2000) found no effects of imatinib on survival of
Bcr-Abl-negative hematopoietic cells after ionizing
radiation.
The question remains whether our ﬁndings are of
importance for the further development of c-Abl kinase
inhibitors. So far, clinical observations do not support a
direct mutagenic effect of imatinib. The increase of
chromosomal aberrations in Philadelphia-negative cells
reported during early clinical studies of imatinib
(Andersen et al., 2002; Terre et al., 2004) is not observed
in patients treated upfront with imatinib. However,
agents with mutagenic capacity such as cigarette
smoking cause malignant disease not before decades of
exposure. Therefore, a carcinogenic risk of imatinib may
become evident only after long-term treatment. Conse-
quently, patients treated for many years with imatinib
should be closely monitored to timely identify unwanted
adverse events.
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